| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1614166 | B | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | 34,209 | ALA1201862 | single protein format | PubChem BioAssays | ||
| 2. | ALA1613829 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1). (Class of assay: confirmatory) [Related pubchem assays: 594 (Rhodamine region spectral profiling screen), 593 (Fluorescein region spectral profiling screen), 2367 (Probe Development Summary for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1)), 2353 (qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1))] | Homo sapiens | 4,515 | ALA1201862 | assay format | PubChem BioAssays | |
| 3. | ALA1613914 | F | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Human Jumonji Domain Containing 2E (JMJD2E). (Class of assay: confirmatory) | Homo sapiens | 39,332 | ALA1201862 | assay format | PubChem BioAssays | |
| 4. | ALA1614211 | F | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | 36,499 | ALA1201862 | assay format | PubChem BioAssays | ||
| 5. | ALA1738090 | F | PUBCHEM_BIOASSAY: qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1477, AID1484] | Homo sapiens | 199 | ALA1201862 | assay format | PubChem BioAssays | |
| 6. | ALA1737904 | F | PubChem BioAssay. qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia: Hit Validation with Orthogonal Assay. (Class of assay: confirmatory) | Homo sapiens | 138 | ALA1201862 | assay format | PubChem BioAssays | |
| 7. | ALA1794352 | F | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | 59,860 | ALA1201862 | assay format | PubChem BioAssays | ||
| 8. | ALA1794483 | F | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | 114,923 | ALA1201862 | assay format | PubChem BioAssays | ||
| 9. | ALA1794580 | F | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | Plasmodium falciparum | 130,890 | ALA1201862 | organism-based format | PubChem BioAssays | |
| 10. | ALA1794584 | F | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | 63,980 | ALA1201862 | assay format | PubChem BioAssays | ||
| 11. | ALA2114775 | F | PubChem BioAssay. qHTS Assay for Inhibitors of Hepatitis C Virus (HCV). (Class of assay: confirmatory) | 75,092 | ALA1201862 | assay format | PubChem BioAssays | ||
| 12. | ALA2114810 | F | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | Homo sapiens | 86,035 | ALA1201862 | assay format | PubChem BioAssays | |
| 13. | ALA4296186 | F | Antibacterial activity against Klebsiella pneumoniae MDR ATCC 70063 (CO-ADD:GN_003); MIC in CAMBH media using NBS plates, by OD(600) | Klebsiella pneumoniae | 6,160 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 14. | ALA4296187 | F | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 (CO-ADD:GN_042); MIC in CAMBH media using NBS plates, by OD(600) | Pseudomonas aeruginosa | 24,161 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 15. | ALA4296189 | F | Antifungal activity against Candida albicans ATCC 90028 (CO-ADD:FG_001); MIC in YNB media using NBS plates, by OD630 | Candida albicans | 6,134 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 16. | ALA4296190 | F | Antifungal activity against Cryptococcus neoformans H99 ATCC 208821 (CO-ADD:FG_002); MIC in YNB media using NBS plates, by Resazurin OD(600-570) | Cryptococcus neoformans | 6,133 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 17. | ALA4296192 | F | Antibacterial activity against Staphylococcus aureus MRSA ATCC 43300 (CO-ADD:GP_020); MIC in CAMBH media using NBS plates, by Resazurin F(560/590) | Staphylococcus aureus | 1,581 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 18. | ALA4296193 | F | Antibacterial activity against Acinetobacter baumannii ATCC 19606 (CO-ADD:GN_034); MIC in CAMBH media using NBS plates, by Resazurin F(560/590) | Acinetobacter baumannii | 1,581 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data | |
| 19. | ALA4296783 | F | Antibacterial activity against Escherichia coli ATCC 25922 (CO-ADD:GN_001); MIC in CAMBH media using NBS plates, by Resazurin F(560/590) | Escherichia coli | 1,581 | ALA4296181 | organism-based format | CO-ADD antimicrobial screening data |
The page will load shortly, Thanks for your patience!